The lesions measured approximately 1

The lesions measured approximately 1.5mm thick on ultrasonography with high internal reflectivity. blurred vision, although studies have reported a 010% incidence rate of asymptomatic lesions in women with metastatic breast cancer. Treatment depends on the general health of the patient, visual symptoms, tumour size, and the presence and activity of other metastases. Commonly, choroidal metastases are treated with external beam radiotherapy or photodynamic therapy,1especially if there is no evidence of systemic metastases. Systemic therapy with hormones or chemotherapy is proven to be effective and represents a better alternative when disease is more widespread.24This case is unique in Guaifenesin (Guaiphenesin) that it demonstrates in photographic form the efficacy of systemic therapy in the treatment of choroidal metastases in a relatively short period of time while maintaining visual acuity and quality of life. The patient has also been followed up for over 18 months and continues to show complete regression of the uveal metastases following treatment with chemotherapy and the biological agent trastuzumab (Herceptin). == Case presentation == A 67-year-old woman with a history of estrogen receptor (ER)-positive and HER2-positive breast cancer treated with surgery, postoperative radiotherapy, chemotherapy, Herceptin and 5 years of adjuvant hormonal therapy, presented with visual disturbances. Choroidal metastases were confirmed by an ocular oncologist. Subsequent investigations revealed bone, liver and lung metastases from an ER-positive and HER2-positive breast tumor. == Investigations == On exam at demonstration, her best corrected visual acuity was 6/18 Guaifenesin (Guaiphenesin) in the right attention and 6/6 in the remaining attention. On funduscopy, two discrete creamy elevated lesions were mentioned in Guaifenesin (Guaiphenesin) the posterior pole of the right eye. The lesions measured approximately 1.5 mm thick on ultrasonography with high internal reflectivity. The looks were consistent with choroidal metastases. == Treatment == The patient was started on weekly paclitaxel chemotherapy and three weekly trastuzumab (Herceptin) in March 2012.Figure 1is the image taken on demonstration. By May 2012, the choroidal metastases experienced regressed significantly having a thickness of 0.4 mm on ultrasonography (figure 2). Visual acuity was maintained. The Rabbit polyclonal to HOXA1 patient completed paclitaxel chemotherapy at the end of June 2012 and remains on a three weekly palliative routine of trastuzumab and tamoxifen. Subsequent ophthalmology review at 6, 12 and 18 months (number 3) confirmed total regression of the metastases with evidence of atrophic looking scars at the site of the previous metastases. No fresh ocular metastases were identified. == Number 1. == Choroidal metastases on demonstration. == Number 2. == Choroidal metastases after 2 weeks of treatment. == Number 3. == Choroidal metastases after 18 months of treatment. == End result and follow-up == The individuals systemic disease responded to the treatment routine with a reduction in the Guaifenesin (Guaiphenesin) size of the liver and lung metastases and regression of the choroidal metastases with preservation of visual acuity. == Conversation Guaifenesin (Guaiphenesin) == Systemic chemotherapy is an effective alternate treatment to external beam radiotherapy when breast cancer is definitely disseminated. In our case we observed a rapid and sustained response to systemic chemotherapy and biological agent with regression of choroidal metastases within 2 weeks and no recurrence at 18 months, with preservation of the individuals visual acuity. Her disease continues to be controlled on the current maintenance treatment regimen of trastuzumab and tamoxifen. Individuals with choroidal metastases from breast cancer have a poor prognosis having a mean survival of approximately 21 weeks from diagnosis.23The role of screening has been considered in a number of recent studies, which have reported the incidence rates of asymptomatic lesions in patients with breast cancer as low as 0%, while older series have reported incidence as high as 9%.45The low incidence rates, however, probably reflect advances in systemic therapies to which choroidal metastases are sensitive. The taxane chemotherapy group in particular, which this individual received, is known to penetrate choroidal cells and is often a popular routine in metastatic breast tumor..